Europe's Most Effective Leaders in Life Science Innovation

1. June Issue 02 2024 Europe's Life Science Industry A Growing Force in Global Healthcare The Power of European Life Science How Leaders Are Transforming Healthcare and Beyond? Most Effective Dr. Vera Rödel Co-founder and CEO Prof. ValMed® Innovation Dr. Va Röd A Visionary Leader Transforming Healthcare through AI

2. Before you are a leader, success is all about growing yourself. When you become a leader, success is all about growing others. - Jack Welch

4. Editor’s Note

5. Influential Minds in Lif e Sciences T intelligence. This synergy is opening doors to possibilities that were once confined to the world of science fiction. True to its scientific excellence tradition, Europe continues to be on the leading edge of these groundbreaking developments. he life sciences sector is currently experiencing significant growth, driven by the integration of artificial overcome a challenge that others might have deemed insurmountable. As you immerse yourself in these pages, you’ll encounter powerful narratives of perseverance, creativity, and scientific acumen. These stories offer more than just a glimpse into the future of life science; they provide a wellspring of inspiration for aspiring innovators and established professionals alike. In this edition, we spotlight ‘Europe’s Most Effective Leaders in Life Science Innovation.’ These pioneers are not just observers of change; they are the catalysts driving transformative advancements in fields such as gene editing, synthetic biology, organ growth, and 3D printing. Their work is revolutionizing our approach to healthcare, environmental challenges, and beyond. We hope that by sharing these accounts of European leadership in life science innovation, we can ignite a flame of curiosity and ambition in our readers. Who knows? The next game- changing idea in this field might come from you. Prepare to be enlightened, challenged and inspired! But what truly sets these leaders apart? It’s their ability to see beyond the status quo, to identify pressing problems, and to forge innovative solutions. Each breakthrough we discuss in this issue began as a spark in someone’s mind – a determined effort to Natalie May Natalie May - Natalie May

6. 08 Dr. Vera Rödel A Visionary Leader Transforming Healthcare through AI Cover Story

7. Profiles 18 Dr. Henk Streefkerk Pioneering the Future of Gene Therapy 26Magdalena Paluch Leading the Future of Scientific Innovation with AI-Driven Solutions Articles 22 Europe's Life Science Industry A Growing Force in Global Healthcare 30 The Power of European Life Science How Leaders Are Transforming Healthcare and Beyond?

8. Editor-in-Chief Thanh Truong Managing Editor Pearl Shaw Executive Editor Natalie May Visualiser David King Art & Design Head Samuel Martinez Co-designer Paul Belin Art & Picture Editor Grace Brown Business Development Manager Emily Jones Business Development Executives Anna Smith, Jack Miller Marketing Manager Bill Thompson Sales Executives Mike, Carl, Ken Technical Consultants David, Robert Assistant Technical Head Joseph Taylor Technical Head Jacob Smile Assistant Digital Marketing Manager Daniel Jones Digital Marketing Manager Alina Sege SME-SMO Executive Gemson Research Analyst Eric Smith Circulation Manager James Carter sales@eurohealthleaders.com June, 2024 Contact Us: Insights Success Media and Technology Pvt. Ltd. Survey No.133/134, Brand Square, Office No. 512, Kunjir Chowk, Pimple Saudagar, Pune, Maharashtra 411027. Phone - India: 7410033802, 8956487823 Email: info@eurohealthleaders.com For Subscription: www.eurohealthleaders.com https://twitter.com/eurohealthleaders Insights Success Media Tech LLC 555 Metro Place North, Suite 100, Dublin, OH 43017, United States Phone - +1614-602-4132 Email: info@eurohealthleaders.com For Subscription: www.eurohealthleaders.com Follow us on : www.facebook.com/eurohealthleaders/ We are also available on : Copyright © 2024 Insights Success Media and Technology Pvt. Ltd., All rights reserved. The content and images used in this magazine should not be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior permission from Insights success. Reprint rights remain solely with Insights Success Media and Technology Pvt. Ltd. Euro Health Leaders is powered by Insights Success Media and Technology Pvt. Ltd.

9. EUROPE'S MOST EFFECTIVE LEADERS IN LIFE SCIENCE INNOVATION Featuring Person Company Brief Christian is a biochemist, chemist, biologist, and serial entrepreneur driven to advance peptide and protein production through innovative technologies. NUMAFERM https://numaferm.com/ Christian Dr. Schwarz CEO Dr. Henk possesses over 15 years of experience in the pharmaceutical industry to lead the company's transformative gene therapy programs. Amarna Therapeutics https://amarna therapeutics.com/ Dr. Henk Streefkerk CEO & Medical Director Dr. Vera is a visionary leader in the healthcare industry, driving the adoption of innovative AI technologies to revolutionize access to validated medical information. Prof. Valmed https://profvalmed.com/ Dr. Vera Rödel CEO & Co-founder Magdalena is a design-driven entrepreneur with over 17 years of experience in building cross- disciplinary teams and leveraging emerging technologies to create innovative products, particularly in the healthcare and mobility sectors. LabTwin https://www. labtwin.com/ Magdalena Paluch CEO & Co-founder Rudolf is an experienced entrepreneur who has founded and co-founded multiple companies in deep technology areas. Nano4Imaging https://www.nano 4imaging.com/ Rudolf Schulze Vohren CEO & Co-founder

10. COVER STORY Dr. Va Röd A Visionary Leader Transforming Healthcare through AI ® The vision of Prof. ValMed aligns seamlessly with my aspirations for a future where healthcare is not only technologically advanced but also deeply human-centric.

11. Dr. Vera Rödel Co-founder and CEO Prof. ValMed®

12. Europe's Most Effec?ve Leaders in Life Science Innova?on I These tools have not only transformed various industries but are also reshaping the healthcare landscape. Healthcare leaders must recognize and harness the potential of these tools to enhance patient outcomes. However, effectively utilizing such tools necessitates insights and distinct leadership qualities. Dr. Rödel, can you walk us through your professional journey and how your background led you to co-found ® Prof. ValMed ? n today's digital age, marked by instant accessibility to information, the significance of advanced tools such as artificial intelligence cannot be understated. Combining my legal expertise with relentless dedication to transforming healthcare, my professional path has been a vibrant blend of legal proficiency and healthcare innovation. With a background as a German attorney holding a Master's degree in Health and Medical Management, my over a decade-long career in various global leadership positions within the pharmaceutical sector has provided me with a deep understanding of the legal complexities in healthcare. Dr. Vera Rödel illustrates this strategic approach at Prof. Valmed validated medical information through an innovative generative AI platform. Co-founded by Dr. Rödel and Prof. Heinz Wiendl, Prof. Valmed aims to elevate healthcare standards by leveraging AI technology to provide accurate and relevant medical data to healthcare professionals. ®, a leading organization committed to delivering As the head of the Global Legal Neurology & Immunology and Cardio Metabolic & Endocrinology Team at Merck Legal Healthcare, I delved into the nuanced legal landscape of healthcare, navigating challenges and shaping strategies on a global scale. This extensive experience became the cornerstone of my journey. ® With a background in law and a Master's degree in Health and Medical Management, Dr. Rödel brings a unique combination of legal insights and healthcare expertise to her role within the company. She plays a crucial role in heading advancements in medical AI at Prof. Valmed , collaborating with esteemed organizations like the Professional Association of German Neurologists to enhance accessibility to medical information. As the Co-founder and CEO of Prof. Valmed , Dr. Rödel leads the charge in redefining how experts and institutions engage with critical medical information. Now, as the co-founder of Prof. ValMed®, I bring a unique perspective to the intersection of law and healthcare innovation. This journey has not only shaped my understanding of legal complexities but has also fueled my passion for creating impactful solutions. Prof. ValMed stands as a manifestation of this commitment, revolutionizing medical information retrieval through an AI-powered platform. ® ® ® From leading legal teams to founding Prof. ValMed , my professional journey is a story of synergizing legal expertise with a vision for transformative healthcare solutions. It's a journey marked by challenges, growth, and a firm belief that innovation can thrive within the bounds of legal excellence. ® Our team had the privilege of interviewing Dr. Rödel, gaining profound insights into her professional journey to learn about the meaningful impact she is making in the industry. Prof. ValMed is known for its groundbreaking platform integrating AI-powered medical information retrieval. What inspired the creation of this platform and how do you envision it transforming the accessibility and reliability of medical data? ® ® Prof. ValMed stands as a manifestation of this commitment, revolutionizing medical information retrieval through an AI-powered platform. The inspiration behind Prof. ValMed stems from a recognition of the critical need for reliable and accessible medical information in the healthcare landscape. As a co- founder, my experiences in both legal healthcare and global neurology highlighted the challenges professionals faced in obtaining validated data efficiently. ®

13. Prof. Heinz Wiendl Co-founder Prof. ValMed®

14. The vision for Prof. ValMed emerged from a desire to bridge this information gap using cutting-edge technology. The integration of AI-powered medical information retrieval was born out of the belief that advanced technologies could revolutionize the way healthcare professionals access and utilize data. By harnessing the capabilities of artificial intelligence, Prof. ValMed aims to transform the accessibility and reliability of medical data. The development of a "medical robot" – as my sons (6 and ® 4) perceive Prof. ValMed – by their mother reflects the potential of innovation to create positive impacts in the healthcare sector – even though Prof. ValMed is not able to fly (yet!). ® ® Prof. ValMed embodies my commitment to driving positive change in healthcare through innovative solutions. It is a testament to the belief that advancements in technology can contribute significantly to the well-being of individuals and communities. ® ® This platform envisions a future where healthcare practitioners can seamlessly access validated information, ensuring the highest standards of quality and precision. By leveraging AI, we aspire to empower medical professionals with a tool that not only expedites information retrieval but also enhances the overall reliability and efficiency of medical data usage. Ultimately, Prof. ValMed strives to be at the forefront of advancing healthcare practices through innovative and reliable information solutions. What leadership principles or values do you prioritize in guiding your team towards achieving the company's goals? ® When it comes to guiding my team towards realizing the company goals, I place great importance on certain leadership principles and values. These include fostering innovation, cultivating collaboration, promoting open communication and upholding ethical decision-making. Additionally, I also emphasize customer-centricity, adaptability and continuous learning to nurture a results- oriented mindset. Could you elaborate on the mission and vision of Prof. ® ValMed and how they reflect your personal values and aspirations in healthcare innovation? The mission and vision of Prof. ValMed align closely with my values and aspirations in healthcare innovation. Prof. ® ValMed aims to revolutionize the accessibility and reliability of medical data, ensuring that healthcare professionals have the tools they need to provide optimal care. This resonates with my personal values, emphasizing the significance of technological innovation in addressing real-world healthcare challenges. ® These values create the foundation for a motivated, supportive, and empowering work environment. What are the key challenges in the current landscape of medical information retrieval and how does Prof. ® ValMed address these challenges? In the current landscape of medical information retrieval, several challenges exist. However, Prof. ValMed is thoughtfully created to address these challenges adeptly: The vision of Prof. ValMed aligns seamlessly with my aspirations for a future where healthcare is not only technologically advanced but also deeply human-centric. ® ® Information Overload: The sheer volume of medical information available can be overwhelming, leading to information overload for healthcare professionals. Prof. ® ValMed employs advanced AI algorithms to filter and present the most relevant and validated information, helping users focus on critical data without being inundated. With my extensive legal background and leadership roles in the pharmaceutical industry, I strategically align ® Prof. Valmed with changing regulatory frameworks. Quality Assurance: Ensuring the accuracy and reliability of medical information is a paramount concern. Prof. ValMed addresses this challenge by providing validated and quality- assured content. Our platform undergoes a rigorous process of data validation to meet high standards of precision and credibility. ®

15. algorithms that adapt to new information, ensuring that the platform remains current and aligned with the latest advancements in the medical field. The development of a “medical robot” – as my sons (6 and 4) perceive Prof. ® Valmed – by their mother reects to them the potential of innovation to create positive impacts in the healthcare sector – even though, Prof. ® Valmed is not able to y (yet!). Prof. ValMed strives to improve medical information retrieval by addressing the above challenges, offering a holistic solution that enhances the efficiency and effectiveness of healthcare professionals in their decision-making processes. ® How do you navigate the balance between innovation and regulatory compliance in the development and implementation of AI-powered solutions in healthcare? Balancing innovation and regulatory compliance when developing and deploying AI-powered solutions in healthcare demands a meticulous approach. With my extensive legal background and leadership roles in the pharmaceutical industry, I strategically align Prof. ValMed with changing regulatory frameworks. This strategic alignment involves ongoing collaboration with regulatory specialists and staying informed about dynamic legal landscapes to ensure our AI platform meets the highest standards of safety, effectiveness, and legal adherence. By implementing robust internal protocols and quality management systems, we reinforce our dedication to innovation while meeting stringent regulatory standards. This seamless integration guarantees that Prof. ValMed not only leads in cutting-edge technology but does so ethically and legally, building trust among users and regulatory bodies. ® Accessibility and Timeliness: Accessing up-to-date medical information in a timely manner is crucial for informed decision-making. Prof. ValMed offers quick and easy access to validated data, saving valuable time for healthcare professionals. The platform's digital accessibility ensures information is available whenever and wherever needed. ® Interoperability: Integration with existing healthcare systems and interoperability with various data sources are common challenges. Prof. ValMed is designed with interoperability in mind, allowing seamless integration with different healthcare environments and facilitating a cohesive flow of information across systems. ® ® Could you highlight some notable achievements or milestones of Prof. ValMed that you are particularly proud of? ® User-Friendly Interface: Many healthcare professionals face challenges with complex interfaces. Prof. ValMed prioritizes user experience by offering a user-friendly interface. The platform's intuitive design enhances usability, making it accessible to a broad range of medical professionals. ® Certainly! Prof. ValMed has achieved several noteworthy milestones that highlight our dedication to transforming medical information retrieval and driving progress in healthcare. Here are some key accomplishments: ® Security and Compliance: Protecting sensitive medical data and ensuring compliance with regulatory standards are critical concerns. Prof. ValMed places a strong emphasis on data security and adheres to all relevant regulations, providing a secure environment for the storage and retrieval of medical information. Strategic Collaboration with Key Healthcare Stakeholders: We have established fruitful collaborations with renowned healthcare institutions, clinical experts, and industry leaders. These partnerships strengthen Prof. ValMed 's position as a reliable and valued resource within the healthcare community, fostering knowledge exchange and further enhancing our platform's capabilities. ® ® Continuous Learning and Updating: Medical knowledge evolves rapidly, requiring constant updates. Prof. ValMed tackles this challenge by employing machine learning ® Validation by Healthcare Professionals: Over 12,000 neurologists have embraced Prof. ValMed , utilizing it as a ®

16. valuable tool in their daily practices. The positive reception from healthcare professionals underscores the platform's efficacy in providing validated and quality-assured medical information. recognition will be built on our unwavering commitment to quality, transparency, and the continuous pursuit of excellence in providing validated medical information. My vision for Prof. ValMed extends beyond its role as a medical information platform. I wish to see it as a driving force for positive transformation in healthcare, influencing practices, nurturing innovation, and ultimately enhancing the health and well-being of individuals and communities globally. ® Progress Toward CE Certification as a Medical Device: As of the current phase, Prof. ValMed is on track towards achieving CE certification as a medical device in Class IIb. This significant milestone, expected in the summer of 2024, will open new avenues for the platform's application in diagnostic and therapeutic support. ® What advice would you give to aspiring leaders in life science? What are your hopes and aspirations for Prof. ValMed and its contribution to advancing healthcare outcomes globally? ® For those aspiring to lead in the life sciences field, I encourage a mindset of embracing innovation and valuing collaboration. Stay attuned to industry advancements and be proactive in seeking out opportunities to contribute to the progress. Additionally, resilience is the key in navigating the inevitable challenges that arise and the transformative power of having a dedicated and enthusiastic team cannot be overstated. Together with passion, dedication and a commitment to excellence, aspiring leaders can make meaningful strides in advancing healthcare for the betterment of all. My hopes and aspirations for Prof. ValMed are deeply rooted in my dedication to enhancing healthcare outcomes on a global scale. As a co-founder, I foresee the platform playing a transformative role in shaping the future of medical information accessibility and contributing significantly to the overall improvement of healthcare worldwide. ® Global Reach and Accessibility: I aspire for Prof. ValMed to reach healthcare professionals and institutions worldwide, transcending geographical boundaries. The platform's innovative approach to medical information retrieval should become a globally accessible and indispensable resource for professionals across diverse healthcare settings. ® Enhancing Diagnostic Accuracy: I envision Prof. ValMed to become an integral part of the diagnostic process, supporting healthcare professionals in making accurate and informed decisions. By harnessing the power of AI and validated medical information, we strive to enhance diagnostic accuracy, ultimately leading to improved patient outcomes. ® Empowering Medical Education: The platform's unique feature of promoting medical education through interactive questions and answers is a cornerstone of our vision. I hope ® that Prof. ValMed becomes a key educational tool, empowering current and future generations of healthcare professionals with up-to-date and reliable medical knowledge. Recognition as a Trusted Healthcare Partner: I aspire for ® Prof. ValMed to be globally recognized as a trusted and indispensable partner in the healthcare ecosystem. This

19. “ The role of a leader in healthcare is to create an environment where people feel empowered to provide the best possible care to patients. - Rana Awdish

20. Europe's Most Effec?ve Leaders in Life Science Innova?on Dr. Henk Streefkerk Pioneering the Future of Gene Therapy D r. Henk Streefkerk stands as the foundation of Amarna Therapeutics' transformative journey. As CEO and Medical Director, Dr. Streefkerk's leadership is both approachable and impactful. With over 15 years of experience, he excels in simplifying complex processes while upholding the highest professional standards. Dr. Streefkerk's expertise in clinical development, regulatory affairs and drug safety is matched only by his dedication to making a difference in patients' lives. His ability to lead diverse teams and navigate regulatory environments has been instrumental in advancing innovative therapies, particularly in gene therapy for conditions like hemophilia B. Dr. Streefkerk's commitment to simplicity, professionalism and effectiveness sets the tone for Amarna's success, ensuring the company remains at the forefront of innovation in the biotechnology sector. Overview of T1DM Type 1 Diabetes Mellitus (T1DM) is an autoimmune disease characterized by the immune-mediated destruction of insulin-producing beta cells within the pancreas. This destruction leads to the absence of insulin, a vital hormone for regulating blood glucose levels. Individuals with T1DM are dependent on lifelong insulin therapy, which does not address the underlying autoimmune destruction of pancreatic beta cells. T1DM typically presents in children and young adults and affects millions worldwide. The associated complications, such as cardiovascular disease, kidney failure and severe hypoglycemia, significantly impact the quality of life and can be life-threatening. Current Treatments for T1DM include: • Insulin Therapy: The mainstay treatment involves multiple daily injections or continuous infusion via a pump to manage blood glucose levels. Pancreatic Islet Transplantation: This involves transplanting islet cells from a donor pancreas into a person with diabetes, but it requires lifelong immunosuppression. Artificial Pancreas Systems: These systems use continuous glucose monitoring and automated insulin delivery to better manage blood sugar levels. Immunotherapy: Recent advancements include drugs like Teplizumab, which help delay the onset of T1DM in at-risk individuals. Let’s explore Dr. Henk Streefkerk's inspiring leadership in gene therapy innovation at Amarna Therapeutics in detail! • Amarna Therapeutics is a small Dutch biotech company at the cutting edge of gene therapy innovation, committed to revolutionizing the treatment paradigm for a broad spectrum of diseases, including autoimmune disorders, metabolic diseases and genetic disorders. Central to our efforts is our proprietary Nimvec platform, a novel gene delivery vector system meticulously engineered to introduce therapeutic genes into the human body both safely and effectively. Our mission is to develop therapies that transcend traditional treatment modalities, aiming for cures where only symptomatic care was previously possible. We believe that the most formidable diseases can be addressed at their genetic roots, offering new hope and transformative solutions for patients across the globe. • • Nimvec AM510: A Revolutionary Approach Our flagship gene therapy product, Nimvec AM510, employs a revolutionary approach to potentially cure Type 1 Diabetes. This therapy utilizes a non-immunogenic vector derived from Simian Virus 40 (SV40), engineered to deliver June 2024 www.eurohealthleaders.com 18

21. Dr. Henk Stree?erk CEO & Medical Director Amarna Therapeu?cs a gene encoding for proinsulin directly to liver cells. This strategy is designed to induce immune tolerance to insulin, potentially reprogramming the immune system to recognize rather than attack pancreatic beta cells. Our mission is to develop therapies that transcend tradi?onal treatment modali?es, aiming for cures where only symptoma?c care was previously possible. Preclinical Efficacy of Nimvec AM510 In the nonclinical studies conducted by Amarna Therapeutics, the administration of Nimvec AM510 demonstrated significant efficacy in preventing the onset of Type 1 Diabetes Mellitus (T1DM) in non-obese diabetic (NOD) mice models. These studies utilized the NOD mice, which spontaneously develop T1DM, making them an ideal model for evaluating the therapeutic potential of new June 2024 www.eurohealthleaders.com 19

22. treatments aimed at modulating autoimmune responses. The results from these rodent model studies were compelling. Mice treated with Nimvec AM510 showed a marked prevention of hyperglycemia, a hallmark of diabetes, indicating effective management of the disease's progression. The treatment was able to induce immune tolerance effectively, which was evident from the sustained normal blood glucose levels in the treated mice compared to the untreated group. As we con?nue to advance our research and development, we remain dedicated to our mission of delivering innova?ve therapies that not only treat but poten?ally cure complex diseases like T1DM. Market Opportunity and Strategic Planning T1DM affects millions worldwide, with an increasing incidence annually. The current treatment landscape, primarily focused on insulin replacement, does not address the autoimmune etiology of the disease. Nimvec AM510, with its potential to halt and possibly reverse T1DM, opens up a vast market opportunity. It offers hope not only for newly diagnosed patients but also for those who have been managing T1DM for years. The strategy for introducing Nimvec AM510 into the market is meticulously planned and supported by a robust framework that leverages the expertise of our Global Scientific Advisory Board. This board comprises distinguished professionals from diverse medical and scientific backgrounds, including endocrinology, genetics and molecular biology, who bring a wealth of knowledge and strategic insight into the complex landscape of autoimmune diseases like Type 1 Diabetes Mellitus (T1DM). Versatility of Nimvec Platform Strategic Alignment with Scientific Advisory Board The Nimvec platform is the cornerstone of our therapeutic strategy. Its non-immunogenic nature allows for the safe delivery of therapeutic genes without eliciting an adverse immune response. This platform is versatile, capable of targeting various diseases beyond T1DM, and offers the potential for re-dosing, a significant advantage over other viral vector systems. The other diseases include Multiple Sclerosis (MS), where Nimvec-based therapies are being explored to modulate the immune system in MS, potentially reducing the frequency and severity of flare-ups, as well as Age-Related Macular Degeneration (AMD): Gene therapies using the Nimvec platform are under investigation to deliver genes that could stop or reverse the damage caused by AMD, preserving vision in aging populations. The board's insights into the latest research and treatment trends enable Amarna to align Nimvec AM510's development with current medical needs and expectations. This strategic alignment is crucial for gaining the trust of regulatory bodies, healthcare providers, and patients. By leveraging the board's expertise, we aim to ensure that our clinical trials are designed to meet the stringent requirements of regulatory agencies, thereby smoothing the path for approval and market entry. Our initial focus will be on securing approval for the use of Nimvec AM510 in adults with T1DM, with subsequent plans to expand indications to pediatric populations. This phased approach allows us to build on the safety and efficacy data gathered from adult trials, thereby mitigating risks and enhancing the therapy's credibility in the market. Each phase of our clinical trials and market introduction is designed to integrate seamlessly, supported by the strategic counsel of our advisory board, ensuring that Nimvec AM510 reaches those in need swiftly and safely. Intellectual Property and Competitive Edge Our IP holdings are extensive, covering innovative aspects of the Nimvec platform and the specific application of June 2024 www.eurohealthleaders.com 20

23. Nimvec AM510 for the treatment of Type 1 Diabetes Mellitus (T1DM). These patents not only protect our unique technology but also ensure a competitive edge in the market. The patents include innovative methods for the production of recombinant polyomaviral vector particles, which are crucial for the efficient and safe delivery of gene therapies. Additionally, our portfolio includes patents for restoring immune tolerance in vivo, a fundamental aspect of our therapeutic approach in autoimmune diseases like T1DM. Moreover, our recent global applications, such as those for anti-inflammatory and regeneration-promoting vectors, expand our IP coverage, ensuring that we stay ahead of the curve in gene therapy innovations. This strong IP position not only secures our advancements but also makes Amarna an attractive partner for collaborations and licensing agreements, further bolstering our market presence and investment potential. form the foundation of our clinical study designs. The upcoming clinical trial will evaluate the safety, efficacy, and tolerability of Nimvec AM510 in human subjects, marking a significant step towards transforming the treatment landscape for T1DM. The success of these trials could herald a new era in the management of this challenging autoimmune disease, bringing us closer to a potential cure and significantly reducing the burden on those affected by T1DM. Looking forward, we envision a future where T1DM is no longer a lifelong burden but a condition that can be cured. Our ongoing experiments and planned clinical trials are a critical step towards realizing this potential. As we continue to advance our research and development, we remain dedicated to our mission of delivering innovative therapies that not only treat but potentially cure complex diseases like T1DM. Progress Towards Clinical Trials Amarna Therapeutics is excited to progress Nimvec AM510 into IND-enabling studies. These nonclinical experiments June 2024 www.eurohealthleaders.com 21

24. A Growing Force in Global Healthcare June 2024 www.eurohealthleaders.com 22

25. Europe's Life Science Industry I n recent years, Europe's life sciences sector has undergone a remarkable transformation, positioning itself as a formidable competitor on the global healthcare stage. This resurgence is built upon a trifecta of strengths: a robust scientific research foundation, an influx of seasoned executive talent, and a surge in venture capital investments. As a result, Europe is now poised to challenge the dominance of established players in the United States and Asia. Scientific Excellence: The Bedrock of Innovation Europe's longstanding reputation for scientific excellence is serving as the cornerstone of its burgeoning life sciences industry. The continent's prestigious universities and research institutions have consistently produced ground- breaking discoveries, laying the groundwork for a thriving biotechnology ecosystem. This scientific prowess is now translating into tangible results, with a proliferation of innovative startups and scale-ups across the region. The United Kingdom, in particular, has witnessed an impressive growth in its biotech sector. Over the past three years, the number of companies engaged in biotechnology research and development has surged by an impressive 75%. Programs such as Nucleate UK and BIA PULSE are playing a crucial role in cultivating a new generation of talented entrepreneurs. These initiatives are facilitating partnerships between budding business leaders and Europe's top scientists, catalyzing the next wave of biotech break- throughs. Talent Acquisition and Capital Influx One of Europe's key advantages in the life sciences arena is its rich pool of executive talent, largely drawn from the pharmaceutical industry. The continent is home to several multinational pharmaceutical giants, including Novartis, Roche, and AstraZeneca. These companies have nurtured a cadre of experienced leaders who are increasingly drawn to the dynamic world of early-stage biotech firms. This influx of seasoned professionals is proving instrumental in scaling up fledgling biotech companies and propelling them towards success. Complementing this talent pool is a significant upswing in venture capital investments. New funds are regularly emerging to compete for the most promising biotech startups, while deep-pocketed US investors are also entering the European market. June 2024 www.eurohealthleaders.com 23

26. Cultivating an Innovation-Friendly Ecosystem as artificial intelligence, cloud computing, and wearable devices, is revolutionizing drug development, clinical trials, and healthcare service delivery. Historically, Europe has been perceived as less ambitious than Silicon Valley in fostering innovation. However, this narrative is rapidly changing. Governments across the continent are implementing policies and incentives designed to create a more favorable environment for life sciences innovation. By embracing these advancements and fostering a culture of innovation, Europe's life sciences industry can drive the development of personalized, data-driven healthcare solutions that improve patient outcomes and reduce the burden on healthcare systems. This shift towards a more citizen-centric, proactive model of healthcare has the potential to solidify Europe's position as a global leader in sustainable and accessible healthcare. The UK's R&D tax credit scheme exemplifies this shift. By providing research-stage companies with significant cash injections, this initiative allows them to extend their operational runway and focus on developing groundbreak- ing therapies. On a broader scale, the European Union is working to streamline the regulatory landscape. The centralized Health Technology Assessment system, slated for implementation in 2025, aims to create a more condu- cive environment for healthcare advancements across the continent. In conclusion, Europe's life sciences industry is on the cusp of a remarkable resurgence. By leveraging its scientific expertise, executive talent, and growing venture capital investments, the continent is positioning itself as a formida- ble force in global healthcare. As it addresses challenges, fosters a conducive environment for innovation, and embraces the future of health, Europe is well-positioned to rival its global counterparts and shape the future of the industry. Addressing Challenges and Inequalities Despite its impressive growth, Europe's life sciences industry faces several challenges. The continent still lags behind the US in terms of venture capital funding for biotech startups. Moreover, there are significant disparities in healthcare access and outcomes across different European countries. The coming years will be crucial in determining whether Europe can fully capitalize on its potential and emerge as a true powerhouse in the global life sciences landscape. With continued investment, supportive policies, and a commit- ment to innovation, the continent has the opportunity to not only compete on the world stage but also to lead the way in developing transformative healthcare solutions that benefit patients worldwide. To address these issues, the European Commission has unveiled a new EU Global Health Strategy. This compre- hensive plan recognizes the need for a profound transforma- tion of European healthcare systems. Key focus areas include digitalization, building a more sustainable healthcare workforce, and incentivizing environmentally friendly healthcare practices. - Natalie May Furthermore, the Commission is working to "level up" healthcare capacity and capability across the continent. The goal is to ensure that all European citizens have access to high-quality healthcare services, regardless of their location. This shift towards a more proactive, prevention- focused model of healthcare is crucial for addressing the rising costs and health inequalities that threaten the sustainability of the current system. Embracing the Future of Health As Europe's life sciences industry continues to evolve, it is poised to play a pivotal role in shaping the future of global healthcare. The integration of emerging technologies, such June 2024 www.eurohealthleaders.com 24

28. Europe’s Most Effective Leaders in Life Science Innovation Magdalena Paluch Leading the Future of Scien?fic Innova?on with AI-Driven Solu?ons M experimentation. With over 17 years of experience as a user experience designer and entrepreneur, Magdalena spearheads LabTwin’s mission to accelerate scientific discovery and innovation in life science laboratories worldwide. agdalena Paluch is the Co-founder and CEO of LabTwin, a pioneering voice-driven digital lab assistant transforming scientific During my tenure as Director at Boston Consulting Group Digital Ventures, I led the building of over ten corporate- backed startups from scratch in Europe and the United States. This opportunity allowed me to hone my skills in fostering innovation within established organizations and navigating the complexities of corporate environments while nurturing an entrepreneurial mindset. Before that, my role as Senior Innovation and Advanced Product Strategist at Toyota exposed me to the cutting-edge world of emerging technologies in mobility and robotics. I was responsible for identifying and implementing innovations such as autonomous vehicle design, further solidifying my appreciation for the transformative power of technology. LabTwin is the world’s first AI- and voice-powered Digital Lab Assistant that enables scientists to seamlessly capture and access their experimental data through natural voice interactions, eliminating disruptive manual documentation. Integrated with lab informatics systems via an open API, LabTwin’s mobile solution empowers researchers to maintain an uninterrupted workflow, ultimately enhancing productivity and accelerating breakthroughs. Today, at LabTwin, my leadership approach is centered on the convergence of design, science and business. I lead a multidisciplinary team of experts, each with unique domain expertise. Our collective mission is to streamline data- driven experimentation in life science labs by leveraging the power of AI and Large Language Models. This holistic approach has enriched my perspective and reinforced my belief in the necessity of cross-functional collaboration to drive meaningful innovation. While LabTwin’s immediate impact is enhancing the efficiency of scientific work, its broader vision is to expedite the delivery of new treatments and therapies to patients globally and foster new science-born innovations that make the world a better place. Let’s dive into the interview details! What are the key innovation strategies and initiatives you have implemented to foster a culture of creativity and problem-solving within your organization? Can you share your journey and the pivotal moments that shaped your leadership approach in driving innovation within the life sciences industry? As a startup pioneering new technology, fostering a culture of creativity and problem-solving is essential at LabTwin. One of our key strategies was and is to assemble a team of passionate individuals who are driven to go the extra mile in cracking complex challenges. We have also curated a team of diverse backgrounds comprising former lab scientists, lab informatics experts, change management A diverse set of experiences across multiple industries has shaped my journey as a leader driving innovation. As a design-driven entrepreneur with over 17 years of hands-on experience, I have had the privilege of building and leading cross-disciplinary teams agilely, primarily within the healthcare and mobility sectors. June 2024 www.eurohealthleaders.com 26

29. Today, at LabTwin, my leadership approach is centered on the convergence of design, science and business. Magdalena Paluch Co-founder and CEO LabTwin short maternity leave during a challenging period for the company. Handing over responsibilities tested our values of empowerment, trust, transparency, and distributed leadership. specialists, data scientists skilled in language models, and software developers. This multidisciplinary composition enables us to approach problems from various angles, unlocking innovative solutions. Our team, led by my co-founder and COO Steffen Gloth and CTO Jonas Kulessa, seamlessly took over my duties, demonstrating our commitment to ownership at every level. This experience validated our belief that open communication and trust enable an organization to thrive even in the absence of key leaders. Collaboration is at the heart of our innovation initiatives. We leverage the Objectives and Key Results (OKR) framework to foster cross-functional synergy, encouraging everyone to contribute to the global OKRs with their unique perspectives and expertise. By aligning our teams around shared objectives, we create an environment that promotes creative problem-solving and enables the free flow of ideas. Returning from leave allowed me to reassess my role, focusing on areas where I could have the most impact while continuing to delegate effectively. This period reinforced the strength of distributed leadership and the resilience of our team. Moreover, we believe in empowering our team members by establishing a culture of ownership at every level. This approach not only unleashes individual creativity but also accelerates decision-making and execution. We trust our team to take calculated risks, experiment with new ideas, and learn from both successes and failures – a mindset essential for driving innovation. What is the biggest challenge for LabTwin in this Life Science Market? One of our biggest challenges in the life science market is our pioneering role in developing a first-of-its-kind product: voice-powered data capture for labs. This entails extensive UX research and solving unprecedented challenges. Additionally, we need to educate scientific organizations about our technology’s value, security, and usability to gain their trust. Could you highlight a significant obstacle you faced in your organization and how you overcame it through effective leadership? One significant obstacle I faced was becoming pregnant while serving as CEO at LabTwin, requiring me to take a June 2024 www.eurohealthleaders.com 27

30. Our target market includes large pharmaceutical companies, chemical giants, and R&D labs, which often have extended sales cycles and complex decision-making processes. Despite navigating these uncharted waters, our team’s passion, expertise, and commitment to innovation drive us forward. By continuously collaborating with our customers and addressing their unique needs, we aim to establish a new paradigm in lab informatics. When bringing AI-driven products to market, trustworthiness is paramount. We use human-in-the-loop automation to ensure our systems make correct decisions and learn appropriately. Our innovations are guided by a deep sense of societal responsibility, ethical awareness, robust security measures, and a commitment to humanity’s greater good. What advice would you offer to aspiring leaders in the life science innovation sector who aim to make a lasting impact and drive transformative change? What are your approaches to attracting, developing, and empowering the next generation of life science innovators? To aspiring leaders in life science innovation, my advice is this: Embrace the relentless pace of change as an opportunity for continuous growth and reinvention. We are in an era where information, technology, and societal norms evolve rapidly. It’s about more than adopting digital tools—it’s about thriving in a paradigm shift where former best practices quickly become the minimum standard. At LabTwin, we foster a culture of purpose and ownership. Our employees often cite the opportunity to work on a pioneering product with modern technologies that can genuinely improve the world as their main motivation. This sense of purpose energizes our team. We translate this purpose into action by encouraging initiative and full project ownership. Empowering our team members to explore their potential and chart their professional growth creates a workplace where people are inspired and never bored. To drive true transformation, cultivate an agile mindset, make swift decisions, ensure security amidst uncertainty, and learn rapidly from successes and failures. Crucially, develop the ability to “unlearn” as quickly as you learn, shedding outdated thinking to keep pace with change. This “speed-unlearning” is vital for innovation. However, empowerment alone is not enough. We invest in our team’s skills and knowledge through continuous learning opportunities, mentorship programs, and exposure to diverse perspectives within the lab digitalization ecosystem. Transformative change isn’t just about personal growth; it’s about empowering and uplifting those around us. Focus on the human experience, leverage empathy, and coach those who need more time to adapt. This creates a ripple effect throughout organizations and industries. As innovation pushes boundaries, ethical considerations become increasingly important. How do you ensure that your organization’s innovative pursuits align with ethical principles and societal well-being? In life sciences, where our work can save lives and improve human conditions, this approach is a moral imperative. By constantly reinventing ourselves and inspiring others, we unlock the full potential of innovation. As innovators, ethical considerations are crucial. We engage diverse experts—product, business, safety, and security—and encourage critical evaluation of our decisions, especially with new technologies. Our customers, including large pharmaceutical organizations, handle highly sensitive information, necessitating unwavering commitment to data safety, security, and privacy. We have robust processes and recurrent audits to maintain certifications like ISO 27001 and 27017, ensuring our IT systems and data processes are secure. Located in Germany, a country with a strong ethical culture, we aim to be a role model. Our blend of cutting-edge technology and stringent security measures sets us apart, emphasizing data safety from the ground up. June 2024 www.eurohealthleaders.com 28

32. The Power of European Life Science How Leaders Are Transforming Healthcare and Beyond? 30 June 2024 www.eurohealthleaders.com

33. T medical practices and address broader societal challenges. Driven by digital innovation, scientific breakthroughs, and a renewed focus on patient-centricity, European life science leaders are charting a course towards a more sustainable, equitable, and impactful healthcare ecosystem. he European life science industry is leading a revolutionary transformation in healthcare, poised to redefine Embracing Digital Transformation At the heart of this transformation is the integration of digital technologies, revolutioniz- ing research, care delivery, and patient engage- ment. European life science companies are leveraging data analytics, artificial intelligence, and connected devices to enable earlier disease detection, personalized treatment approaches, and more efficient clinical trials. These digital innovations are not only improv- ing patient outcomes but also driving cost- effectiveness and sustainability within healthcare systems. By harnessing real-world data and predictive analytics, European life science leaders can anticipate and proactively address emerging health challenges, shifting away from traditional reactive care models. Advancing Precision Medicine Alongside digital transformation, European life science is at the forefront of precision medicine, tailoring treatments to individuals' unique genetic, environmental, and lifestyle factors. Through advancements in genomics, biomarker research, and targeted therapies, European companies are delivering more effective and personalized care, improving patient outcomes and reducing the burden on healthcare systems. The European Union's Orphan Drug Regulation has been instrumental in this area, incentivizing the development of treatments for rare diseases and fostering a vibrant research community dedicated to improving the lives of patients with rare conditions. June 2024 www.eurohealthleaders.com 31

34. Fostering Multistakeholder Collaboration Shaping a Healthier Future Recognizing the complexity of the healthcare landscape, European life science leaders are embracing a collaborative approach, forging partnerships across public and private sectors. These multistakeholder initiatives enable the sharing of data, expertise, and resources to accelerate innovation and address unmet patient needs. As European life science leaders continue to drive innova- tion and collaboration, the impact extends far beyond the healthcare sector. Advancements in precision medicine, digital health, and patient-centric care have the potential to improve overall societal well-being, addressing complex challenges such as rising health inequalities and the impact of climate change on public health. For instance, numerous research and development partner- ships across multiple countries demonstrate the power of collaboration in driving progress. These initiatives bring together diverse expertise to tackle complex health challenges and accelerate the development of innovative therapies. By 2040, the European healthcare landscape is envisioned to be radically different, with a focus on proactive health promotion, prevention, and personalized care. This transformation, if realized, will not only extend the lives of European citizens but also solidify the continent's position as a global leader in sustainable and accessible healthcare. Prioritizing Patient-Centricity In conclusion, the European life science industry is at the forefront of a transformative shift, leveraging digital innovation, scientific breakthroughs, and a collaborative, patient-centric approach to redefine the future of healthcare and beyond. As European leaders continue to push the boundaries of what is possible, the impact on individual well-being, societal health, and global competitiveness is poised to be profound. At the core of the European life science transformation is a renewed focus on patient-centricity. Companies are placing patients' needs and experiences at the center of their innovation efforts, ensuring that new treatments, technolo- gies, and care models are designed to improve quality of life. This shift towards patient-centricity is not only improving outcomes but also fostering greater trust and engagement between patients and healthcare providers. By addressing the unique challenges faced by individuals, particularly those living with rare or complex diseases, European life science leaders are paving the way for a more inclusive and equitable healthcare system. From developing groundbreaking gene therapies to creating AI-powered diagnostic tools, these advancements are opening new frontiers in medical science and patient care. The ongoing digital revolution in healthcare is set to accelerate, with technologies like blockchain enhancing data security and interoperability, and virtual reality transforming medical training and patient rehabilitation. Addressing Systemic Challenges As we navigate an increasingly complex global health landscape, the promise of European life science shines bright. By continuing to foster innovation, embrace emerging technologies, and prioritize patient needs, these industry leaders are charting a course towards a healthier, more equitable, and sustainable future for all. While the European life science industry is leading the charge in transforming healthcare, it faces significant challenges. Disparities in access to innovative treatments, regulatory complexities, and the need for sustainable financing models remain pressing issues that require coordinated action. - Natalie May European policymakers have recognized these challenges and are taking steps to address them. Initiatives like the European Commission's EU Global Health Strategy aim to strengthen healthcare capacity and capability across the continent, fostering a more resilient and equitable healthcare ecosystem. June 2024 www.eurohealthleaders.com 32

35. Stay in touch. Subscribe to Euro Health Leaders and get the magazine in print, & digital on www.eurohealthleaders.com Email: info@eurohealthleaders.com For Subscription: www.eurohealthleaders.com

36. www.eurohealthleaders.com